Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Optic Nerve Glioma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Choroid Plexus Neoplasms 1Carcinoma, Renal Cell 1Blast Crisis 1

Interventions

Cisplatin 19Docetaxel 17Cetuximab 12Carboplatin 12Radiotherapy 11Magnetic Resonance Spectroscopy 10Biopsy 10pembrolizumab 9Paclitaxel 9Radiotherapy, Intensity-Modulated 8Immunohistochemistry 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiotherapy, Conformal 5Radiosurgery 5Gene Expression Profiling 5Fluorodeoxyglucose F18 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Polymerase Chain Reaction 4Nivolumab 4Bevacizumab 4trastuzumab deruxtecan 3sargramostim 3bicalutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × CK0238273 × Clear all
NCT00095628 2017-03-06

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡